Skip to main content

Table 1 Patient’s demographic characteristics and vitreous hemorrhage score at baseline

From: Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial

  Group A Group B p
Age (Mean ± SD) 63.66 ± 8.16 64.03 ± 11.24 0.8475
Gender 15 M//20 F 18 M//17 F 0.1470
SAH (n) 34 34 0.5072
Lens Status
(phakic / pseudophakic)
28 (80.0)/7 (20.0) 31 (88.58)/4 (11.42)  
Previous PRP (%) 16 (45.7) 13 (37.1) 0.4667
Partial PRP * 8 (22.85) 9 (25.8)
Complete PRP 8 (22.85) 5 (14.3)
Baseline VH Score (%)   0.3735
Grade 1 3 (8.6) 1 (2.9)
Grade 2 14 (40) 11 (31.4)
Grade 3 18 (51.4) 23 (65.7)
  1. SAH systemic arterial hypertension, M male, F female, PRP panretinal photocoagulation, VH vitreous hemorrhage
  2. * ≤ 3 quadrants of full scatter PRP